Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
437.15
+2.63 (+0.61%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
68
69
Next >
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Prime Candidate for Value Investors
↗
August 26, 2025
Vertex Pharmaceuticals (VRTX) is a top value stock with strong financials, high profitability, and impressive growth, trading below its biotech peers.
Via
Chartmill
This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy?
↗
August 24, 2025
It's been an unusually bad year for this drugmaker, but it's essential to look beyond that.
Via
The Motley Fool
Topics
Law Enforcement
Stocks
2 Beaten-Down Stocks With Incredible Upside Potential
↗
August 22, 2025
These stocks should be able to rebound strongly.
Via
The Motley Fool
Vertex to Participate in Upcoming September Investor Conferences
August 20, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Unusual Options Activity
↗
August 06, 2025
Via
Benzinga
What's Wrong With Vertex Pharmaceuticals Stock?
↗
August 20, 2025
Shares of the pharma company are down 17% in the past 12 months.
Via
The Motley Fool
2 Nasdaq 100 Stocks to Consider Right Now and 1 Facing Challenges
August 19, 2025
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...
Via
StockStory
Trump 2.0 At 200 Days: Palantir Surges, Tesla Slumps
↗
August 18, 2025
Palantir leads all stocks in the S&P 500 with a stunning 160% gain in Trump's first 200 days.
Via
Benzinga
Topics
Government
Stocks
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
↗
August 17, 2025
This biotech's innovative approach could pay rich dividends down the road.
Via
The Motley Fool
3 Fantastic Growth Stocks to Buy in August
↗
August 17, 2025
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.
Via
The Motley Fool
Is This Beaten-Down Stock a Buy on the Dip?
↗
August 15, 2025
It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive entry point.
Via
The Motley Fool
2 Growth Stocks That Are No-Brainer Buys Right Now
↗
August 15, 2025
These stocks have outperformed broader equities over the past decade and still have room to run.
Via
The Motley Fool
VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market
August 12, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the...
Via
StockStory
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
↗
August 11, 2025
Via
Benzinga
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
↗
August 11, 2025
Via
Benzinga
Exploring the top movers within the S&P500 index during today's session.
↗
August 11, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
1 Cash-Producing Stock for Long-Term Investors and 2 We Brush Off
August 11, 2025
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via
StockStory
Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio?
↗
August 10, 2025
Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly.
Via
Benzinga
The Smartest Growth Stocks to Buy With $1,000 Right Now
↗
August 09, 2025
There's no guarantee that any stock will beat the market, but the chances look good for these three.
Via
The Motley Fool
Topics
Artificial Intelligence
5 Top Stocks to Buy in August
↗
August 08, 2025
Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.
Via
The Motley Fool
Topics
Economy
Stocks
Unusual volume S&P500 stocks in Thursday's session
↗
August 07, 2025
Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.
Via
Chartmill
The Best Stocks to Invest $1,000 In Right Now
↗
August 07, 2025
Market volatility could increase in the months ahead, but these stocks should hold up well.
Via
The Motley Fool
Topics
Economy
Government
World Trade
Which S&P500 stocks have an unusual volume on Wednesday?
↗
August 06, 2025
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
Via
Chartmill
Which S&P500 stocks are moving on Wednesday?
↗
August 06, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via
Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Strong Affordable Growth Pick with Solid Fundamentals
↗
August 06, 2025
Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors.
Via
Chartmill
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip
↗
August 06, 2025
There's more good news than bad news for this big biotech stock.
Via
The Motley Fool
Topics
Earnings
Market Monitor News August 06 BMO - Wall Street Slides as Services Sector Falters, but Palantir Rockets Past Expectations
↗
August 06, 2025
A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.
Via
Chartmill
Topics
Economy
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today
August 05, 2025
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial....
Via
StockStory
Topics
Artificial Intelligence
Top S&P500 movers in Tuesday's session
↗
August 05, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Via
Chartmill
Weakness In Vertex Stock Seen As Buying Opportunity
↗
August 05, 2025
Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
68
69
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today